Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.44 |
| ▸ | HRH1 | P35367 | 4/20 | 0.44 |
| ▸ | HRH2 | P25021 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.44 |
| ▸ | DRD1 | P21728 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875920 | 0.95 | DRD2 (0.44) | DRD2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17589604 | 0.81 | SETD7 (0.40) | DRD2DRD4MAPTHRH4CHRM2 | |
| SCHEMBL14985777 | 0.76 | FNTA (0.37) | DRD4HRH4HRH1ADRA2AHTR2A | |
| SCHEMBL10733741 | 0.73 | DRD4 (0.57) | DRD2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13752344 | 0.73 | DRD4 (0.48) | DRD2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11364230 | 0.72 | SETD7 (0.53) | DRD2DRD4MAPTHRH4CHRM2 | |
| Clopipazan SCHEMBL1816896 | 0.71 | SETD7 (0.76) | DRD2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11654908 | 0.69 | MAPK1 (0.43) | DRD2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11648575 | 0.69 | MAPK1 (0.43) | DRD2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12070616 | 0.69 | MAPK1 (0.51) | DRD2DRD4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11535628-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-4015519-A1 | METHOD OF PREPARING ASENAPINE | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021027813-A1 | METHOD OF PREPARING ASENAPINE | 浙江奥翔药业股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20210047339-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-9145421-B2 | Process for the preparation of asenapine maleate | RANBAXY LABORATORIES LIMITED (IN) | 2015-09-29 | — | — | US | disclosed |
| US-9145421-B2 | Process for the preparation of asenapine maleate | RANBAXY LABORATORIES LIMITED (IN) | 2015-09-29 | — | — | US | disclosed |
| US-9145421-B2 | Process for the preparation of asenapine maleate | RANBAXY LABORATORIES LIMITED (IN) | 2015-09-29 | — | — | US | disclosed |
| US-20150112083-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE MALEATE | RANBAXY LABORATORIES LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| EP-2154134-A1 | Process for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole. | N.V. Organon (NL) | 2010-02-17 | — | — | EP | disclosed |
| EP-2154134-A1 | Process for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole. | N.V. Organon (NL) | 2010-02-17 | — | — | EP | disclosed |
| US-20090209608-A1 | DEUTERIUM-ENRICHED ASENAPINE | PROTIA, LLC (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209608-A1 | DEUTERIUM-ENRICHED ASENAPINE | PROTIA, LLC (US) | 2009-08-20 | — | — | US | disclosed |
| US-20080214832-A1 | Process for making asenapine | SYNTHON BV (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214832-A1 | Process for making asenapine | SYNTHON BV (NL) | 2008-09-04 | — | — | US | disclosed |
| WO-2008081010-A1 | PROCESS FOR MAKING ASENAPINE | SYNTHON B.V. (NL) | 2008-07-10 | — | — | WO | disclosed |
| US-20060229352-A1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | ORGANON IRELAND LTD. (IE) | 2006-10-12 | — | — | US | disclosed |
| US-20060229352-A1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | ORGANON IRELAND LTD. (IE) | 2006-10-12 | — | — | US | disclosed |
| EP-1710241-A1 | Intermediate compounds for the prepation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | Organon Ireland Ltd. (IE) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | CYP3A5, QDPR, SPR | DRD2 39/4885DRD4 37/4885CYP1A2 139/4885 |
| US-20060229352-A1 | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole | DHPS, ODC1, OXTR | DRD2 213/4885DRD4 198/4885CYP1A2 44/4885 |
| US-11535628-B2 | Method for preparation of Asenapine | CYP3A5, QDPR, SPR | DRD2 39/4885DRD4 37/4885CYP1A2 139/4885 |
| US-20090209608-A1 | DEUTERIUM-ENRICHED ASENAPINE | NSD2, DRD2, SNRPD2 | DRD2 2/4885DRD4 17/4885CYP1A2 646/4885 |
| US-20080214832-A1 | Process for making asenapine | CYP3A5, CYP3A4, CYP2C9 | DRD2 57/4885DRD4 88/4885CYP1A2 11/4885 |
| US-20210047339-A1 | METHOD FOR PREPARATION OF ASENAPINE | CYP3A5, QDPR, SPR | DRD2 39/4885DRD4 37/4885CYP1A2 139/4885 |
| US-20150112083-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE MALEATE | DHPS, SCN5A, CYP3A5 | DRD2 999/4885DRD4 903/4885CYP1A2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.